

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting the clinic

Ca-A Cancer Journal for Clinicians

61, 31-49

DOI: [10.3322/caac.20095](https://doi.org/10.3322/caac.20095)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Fast repair of DNA radicals in the earliest stage of carcinogenesis suppresses hallmarks of cancer. RSC Advances, 2011, 1, 1610.	1.7	7
2	The changing therapeutic landscape of castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 597-610.	12.5	137
3	Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature, 2011, 475, 231-234.	13.7	939
4	The Ups and Downs of Tannins as Inhibitors of Poly(ADP-Ribose)glycohydrolase. Molecules, 2011, 16, 1854-1877.	1.7	28
5	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer Cell, 2011, 19, 573-574.	7.7	15
6	Management of Women With BRCA Mutations. JAMA - Journal of the American Medical Association, 2011, 305, 2211.	3.8	27
7	Genetics of breast cancer: Contribution of BRCA1/2 genes alterations to hereditary predisposition. Vojnosanitetski Pregled, 2012, 69, 700-706.	0.1	4
8	Classification, Molecular Characterization, and the Significance of Pten Alteration in Leiomyosarcoma. Sarcoma, 2012, 2012, 1-8.	0.7	19
9	BRCAness: Finding the Achilles Heel in Ovarian Cancer. Oncologist, 2012, 17, 956-962.	1.9	86
10	Targeting the DNA damage response in oncology. Current Opinion in Oncology, 2012, 24, 316-324.	1.1	52
12	Targeting Homologous Recombination Repair in Cancer. , 2012, , 119-160.		7
13	The Role of PARP in DNA Repair and its Therapeutic Exploitation. , 2012, , 55-73.		2
14	Blockade of Base Excision Repair. , 2012, , 29-53.		5
16	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	4.2	96
17	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	7.7	354
18	A Force Field with Discrete Displaceable Waters and Desolvation Entropy for Hydrated Ligand Docking. Journal of Medicinal Chemistry, 2012, 55, 623-638.	2.9	216
19	A snapshot of chemoresistance to PARP inhibitors. Trends in Pharmacological Sciences, 2012, 33, 42-48.	4.0	37
20	The NAD metabolome â€” a key determinant of cancer cell biology. Nature Reviews Cancer, 2012, 12, 741-752.	12.8	487

#	ARTICLE	IF	CITATIONS
21	Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?. Trends in Molecular Medicine, 2012, 18, 92-100.	3.5	22
22	Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters, 2012, 319, 232-241.	3.2	45
23	Defective homologous recombination in human cancers. Cancer Treatment Reviews, 2012, 38, 89-100.	3.4	60
24	Emerging therapies for urothelial cancer. Cancer Treatment Reviews, 2012, 38, 311-317.	3.4	8
25	PARP Inhibitors. Drugs, 2012, 72, 1579-1590.	4.9	36
26	Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. Future Medicinal Chemistry, 2012, 4, 51-72.	1.1	21
27	Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene, 2012, 31, 5099-5107.	2.6	44
28	Extensive Gene-Specific Translational Reprogramming in a Model of B Cell Differentiation and Abl-Dependent Transformation. PLoS ONE, 2012, 7, e37108.	1.1	8
29	Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. Journal of Oncology, 2012, 2012, 1-23.	0.6	39
30	Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Medicinal Chemistry, 2012, 4, 1093-1111.	1.1	21
31	Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. International Journal of Cancer, 2012, 131, 2433-2444.	2.3	79
32	Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon- β . Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 691-701.	2.2	6
33	The growing complexity of HIF-1's role in tumorigenesis: DNA repair and beyond. Oncogene, 2013, 32, 3569-3576.	2.6	72
34	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncology, The, 2013, 14, 882-892.	5.1	497
35	Cancer of the Breast and Female Reproductive Tract. , 2013, , 1-31.		1
36	Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver. Toxicology and Applied Pharmacology, 2013, 266, 260-266.	1.3	7
37	Genetically engineered mouse models of PI3K signaling in breast cancer. Molecular Oncology, 2013, 7, 146-164.	2.1	34
38	A zinc finger nuclease assay to rapidly quantitate homologous recombination proficiency in human cell lines. Analytical Biochemistry, 2013, 434, 96-98.	1.1	8

#	ARTICLE	IF	CITATIONS
39	New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. BioMed Research International, 2013, 2013, 1-13.	0.9	22
40	Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biology and Therapy, 2013, 14, 537-545.	1.5	35
41	The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Frontiers in Oncology, 2013, 3, 228.	1.3	95
42	Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 2013, 122, 1293-1304.	0.6	125
43	The Level of Ets-1 Protein Is Regulated by Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Cancer Cells to Prevent DNA Damage. PLoS ONE, 2013, 8, e55883.	1.1	27
44	DNA Repair and Resistance to Cancer Therapy. , 0, , .		2
45	The Role of PARP Activation in Prostate Cancer. , 0, , .		1
46	Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2014, 6, 229-239.	1.4	189
47	Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells. Cell Death and Disease, 2014, 5, e1400-e1400.	2.7	31
48	Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts. Neoplasia, 2014, 16, 982-991.	2.3	37
49	Long-term suppression of <sc>EAE</sc> relapses by pharmacological impairment of epitope spreading. British Journal of Pharmacology, 2014, 171, 1501-1509.	2.7	10
50	Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Frontiers in Oncology, 2014, 4, 42.	1.3	76
51	New concepts in breast cancer genomics and genetics. Breast Cancer Research, 2014, 16, 460.	2.2	28
52	Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian Journal of Andrology, 2014, 16, 401.	0.8	14
53	INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. Tumor Biology, 2014, 35, 4469-4477.	0.8	14
54	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	0.9	135
55	A short review on the implications of base excision repair pathway for neurons: Relevance to neurodegenerative diseases. Mitochondrion, 2014, 16, 38-49.	1.6	48
56	Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug-Induced DNA Damage under Hypoxia. Molecular Pharmacology, 2014, 85, 866-876.	1.0	28

#	ARTICLE	IF	CITATIONS
57	Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 201-215.	3.3	89
58	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33.	2.2	138
59	DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles™ Heel of Cancer. <i>Biomolecules</i> , 2015, 5, 3204-3259.	1.8	85
60	African Flora Has the Potential to Fight Multidrug Resistance of Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-24.	0.9	151
61	Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e222-e227.	1.8	1
62	Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis. <i>BMC Cancer</i> , 2015, 15, 369.	1.1	4
63	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i> -Mutated and <i>BRCA</i> “Wild-Type Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 920-930.	1.9	62
64	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015, 113, 396-402.	2.9	42
65	Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities. <i>Journal of Clinical Oncology</i> , 2015, 33, 1779-1786.	0.8	66
66	Pharmacological NAD-Boosting Strategies Improve Mitochondrial Homeostasis in Human Complex I“Mutant Fibroblasts. <i>Molecular Pharmacology</i> , 2015, 87, 965-971.	1.0	26
67	Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1397-1406.	0.8	295
68	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. <i>Cancer Discovery</i> , 2015, 5, 1137-1154.	7.7	657
69	ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138.		487
70	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. <i>Oncogene</i> , 2015, 34, 1745-1757.	2.6	147
71	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. <i>Oncogene</i> , 2015, 34, 2815-2822.	2.6	81
72	Understanding the basics for translating the base excision repair pathway from benchtop to bedside in cancer treatment. , 2016, , 83-114.		1
73	PARP inhibitors: the race is on. <i>British Journal of Cancer</i> , 2016, 114, 713-715.	2.9	135
74	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 3894-3902.	3.2	23

#	ARTICLE	IF	CITATIONS
75	PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. <i>British Journal of Cancer</i> , 2016, 115, 1157-1173.	2.9	163
76	Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. <i>Endocrine-Related Cancer</i> , 2016, 23, T57-T67.	1.6	16
77	Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2302-2313.	1.9	5
78	Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. <i>Nuclear Medicine and Biology</i> , 2016, 43, 752-758.	0.3	25
79	A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2620-2629.	1.9	23
80	Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. <i>Endocrine-Related Cancer</i> , 2016, 23, R267-R285.	1.6	28
81	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016, 26, 87-99.	0.9	142
82	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1699-1712.	3.2	95
83	Poly(ADP-ribose) polymerase activity and inhibition in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2017, 63, 144-153.	2.3	47
84	TIRR regulates 53BP1 by masking its histone methyl-lysine binding function. <i>Nature</i> , 2017, 543, 211-216.	13.7	96
85	Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. <i>International Journal of Clinical Oncology</i> , 2017, 22, 611-618.	1.0	10
86	Targeting ATR in cancer medicine. <i>Current Problems in Cancer</i> , 2017, 41, 302-315.	1.0	43
87	PARP Inhibitors in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 37.	1.3	50
88	Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 20-37.	7.7	488
89	Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy. <i>Cell Chemical Biology</i> , 2017, 24, 1101-1119.	2.5	111
91	Reverse the Resistance to PARP Inhibitors. <i>International Journal of Biological Sciences</i> , 2017, 13, 198-208.	2.6	67
92	A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. <i>BMC Cancer</i> , 2017, 17, 540.	1.1	9
93	Advances in ovarian cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 17-38.	1.1	393

#	ARTICLE	IF	CITATIONS
94	LncRNAs in DNA damage response and repair in cancer cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 433-439.	0.9	49
95	FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. <i>Journal of Genetic Counseling</i> , 2018, 27, 131-139.	0.9	21
96	Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 8063-8074.	3.3	11
97	The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. <i>Nature Reviews Cancer</i> , 2018, 18, 696-705.	12.8	1,059
98	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018, 70, 168-177.	3.4	55
99	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
100	Can Early Clinical Trials Help Deliver More Precise Cancer Care?. , 2018, , 115-128.		0
101	Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52â€™ssDNA association. <i>RSC Advances</i> , 2018, 8, 18859-18869.	1.7	9
102	Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. <i>Cancers</i> , 2018, 10, 49.	1.7	31
103	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
104	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878665.	1.4	105
105	Emerging therapeutic modalities of PARP inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 62-68.	3.4	28
106	Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?. <i>Current Oncology Reports</i> , 2018, 20, 63.	1.8	2
107	Overcoming Resistance to PARP Inhibition. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 161-189.	0.1	0
108	Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111621.	2.6	52
109	Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. <i>Communications Biology</i> , 2019, 2, 335.	2.0	35
110	The multi-factorial nature of clinical multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100645.	6.5	324
111	Î±-Humulene inhibits hepatocellular carcinoma cell proliferation and induces apoptosis through the inhibition of Akt signaling. <i>Food and Chemical Toxicology</i> , 2019, 134, 110830.	1.8	37

#	ARTICLE	IF	CITATIONS
112	BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22286.	1.4	5
113	Integrated Analysis of the Altered lncRNAs and mRNAs Expression in 293T Cells after Ionizing Radiation Exposure. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2968.	1.8	14
114	Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 4542-4551.	3.2	19
115	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	0.8	133
116	Ovarian cancer stem cells and targeted therapy. <i>Journal of Ovarian Research</i> , 2019, 12, 120.	1.3	70
117	Role of Human Xeroderma Pigmentosum Group D (XPD) Helicase in Various Cellular Pathways. , 2019, , 125-139.		2
118	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). <i>Investigational New Drugs</i> , 2020, 38, 1117-1128.	1.2	10
119	TGF β 2R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. <i>Cell Reports</i> , 2020, 33, 108221.	2.9	18
120	Design, synthesis and <i>in silico</i> studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors. <i>RSC Advances</i> , 2020, 10, 29475-29492.	1.7	39
121	Epidemiology and Genetic Susceptibility of Breast and Ovarian Cancer in Sardinian Population. , 0, , .		0
122	Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases. <i>British Journal of Cancer</i> , 2020, 122, 1219-1230.	2.9	56
123	DNA Damage/Repair Management in Cancers. <i>Cancers</i> , 2020, 12, 1050.	1.7	166
124	Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 319.	1.3	44
125	Dehydrocostus lactone inhibits cell proliferation and induces apoptosis by PI3K/Akt/Bad and ERS signalling pathway in human laryngeal carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6028-6042.	1.6	23
127	CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5869.	1.8	7
128	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Na \tilde{v} e Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. <i>Clinical Cancer Research</i> , 2021, 27, 3884-3895.	3.2	40
129	In silico design, ADMET screening, MM-GBSA binding free energy of novel 1,3,4 oxadiazoles linked Schiff bases as PARP-1 inhibitors targeting breast cancer. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	12
130	Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytochemistry. <i>Phytochemistry</i> , 2021, 91, 153718.	2.3	5

#	ARTICLE	IF	CITATIONS
131	Genetic Instability of Cancer: Biological Predictions and Clinical Implications. , 2013, , 81-84.		4
132	Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN- γ . PLoS ONE, 2013, 8, e73616.	1.1	54
133	Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. PLoS ONE, 2016, 11, e0147230.	1.1	55
134	“Back to a false normality” new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	0.8	24
135	Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. Oncotarget, 2019, 10, 6981-6996.	0.8	9
136	Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. Oncotarget, 2020, 11, 1653-1665.	0.8	4
137	NF- κ B signaling mediates acquired resistance after PARP inhibition. Oncotarget, 2015, 6, 3825-3839.	0.8	35
138	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget, 2015, 6, 15008-15021.	0.8	32
139	High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget, 2015, 6, 16951-16962.	0.8	28
140	DNA Double Strand Break Repair - Related Synthetic Lethality. Current Medicinal Chemistry, 2019, 26, 1446-1482.	1.2	9
141	Genomic predictors for treatment of late stage prostate cancer. Asian Journal of Andrology, 2016, 18, 586.	0.8	7
142	CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery. FEBS Journal, 2021, , .	2.2	5
143	Assessing cognitive toxicity in early phase trials “What are we missing?”. Psycho-Oncology, 2021, , .	1.0	0
144	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. Genes, 2021, 12, 1593.	1.0	2
145	Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. Cancer Research, 2012, 72, IA9-IA9.	0.4	0
146	Targeting DNA Repair Pathways for Cancer Therapy. , 2013, , 137-180.		1
147	DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy?. , 2013, , 25-44.		1
148	G-Protein-Coupled Receptor (GPCR)-Dependent ADAM-17 Regulated Ectodomain Shedding. , 2012, , 124-145.		0

#	ARTICLE	IF	CITATIONS
149	IONIZING RADIATION. , 2013, , 111-112.		0
150	Invasive breast carcinoma. , 2013, , 266-285.		0
151	Ovarian Cancer: BRCA Genetics Reveals Targets for New Therapies. Journal of Genetic Syndromes & Gene Therapy, 2014, 05, .	0.2	0
152	Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. Cancer Drug Discovery and Development, 2015, , 381-412.	0.2	0
153	PARP Inhibitor Resistanceâ€”What Is Beyond BRCA1 or BRCA2 Restoration?. Cancer Drug Discovery and Development, 2015, , 453-471.	0.2	0
154	Biomarkers for Early Detection of Familial Breast Cancer. , 2015, , 167-190.		0
156	Bad Smells and Broken DNA: A Tale of Sulfur-Nucleic Acid Cooperation. Antioxidants, 2021, 10, 1820.	2.2	3
157	BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	11
158	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. Oncologist, 2022, 27, 30-39.	1.9	10
159	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
160	The role of PARP inhibitors in gastrointestinal cancers. Critical Reviews in Oncology/Hematology, 2022, 171, 103621.	2.0	7
161	Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response. International Journal of Molecular Sciences, 2022, 23, 3555.	1.8	11
162	Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancerâ€”An Opportunity for Targeted Therapy. Diagnostics, 2022, 12, 842.	1.3	15
163	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers, 2022, 14, 1821.	1.7	3
164	Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy. Frontiers in Bioengineering and Biotechnology, 2022, 10, 904344.	2.0	7
165	PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications. Biomedicine and Pharmacotherapy, 2022, 153, 113458.	2.5	5
166	Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. European Journal of Medicinal Chemistry, 2022, 243, 114790.	2.6	10
167	Design, synthesis and molecular modeling study of certain quinazolinone derivatives targeting poly(ADP-ribose) polymerase 1 (PARP-1) enzyme as anti-breast cancer and radio-sensitizers. Journal of Molecular Structure, 2023, 1273, 134358.	1.8	6

#	ARTICLE	IF	CITATIONS
168	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. <i>Cancers</i> , 2022, 14, 5795.	1.7	4
169	Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. <i>Cancers</i> , 2022, 14, 5922.	1.7	2
170	CD133 as Biomarker and Therapeutic Target in Gynecologic Malignancies. , 2023, , .		1
171	Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1. <i>European Journal of Medicinal Chemistry</i> , 2023, 251, 115243.	2.6	1
172	Mechanism of PARP inhibitor resistance and potential overcoming strategies. <i>Genes and Diseases</i> , 2024, 11, 306-320.	1.5	7
178	Advancing Precision Medicine. , 2024, , 1-31.		0